Liminal BioSciences Inc. (https://liminalbiosciences.com) is a global biotechnology company that specialises in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. We focus specifically on developing solutions for rare and orphan diseases. Liminal BioSciences operates on an integrated basis from our three talent hubs in Laval, Quebec, Canada, Cambridge, UK and Rockville, Maryland, USA. Our common shares are listed for trading on the Toronto Stock Exchange (Symbol:LMNL).



Contact Information
Liminal BioSciences Inc.
[email protected]
+1.450.781.0115 

Latest

Apr 14, 2015, 16:33 ET ProMetic Announces $50 Million Bought Deal Offering to Fund Strategic Growth Initiatives

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/ LAVAL, QC, April ...

Nov 18, 2014, 16:34 ET ProMetic Announces $25.1 Million Bought Deal Offering to Fund Strategic Growth Initiatives

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES LAVAL, QC, Nov....

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE